全文获取类型
收费全文 | 700篇 |
免费 | 57篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 32篇 |
妇产科学 | 5篇 |
基础医学 | 49篇 |
口腔科学 | 32篇 |
临床医学 | 60篇 |
内科学 | 172篇 |
皮肤病学 | 22篇 |
神经病学 | 15篇 |
特种医学 | 132篇 |
外科学 | 78篇 |
综合类 | 78篇 |
预防医学 | 18篇 |
药学 | 37篇 |
1篇 | |
肿瘤学 | 32篇 |
出版年
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 10篇 |
2015年 | 14篇 |
2014年 | 17篇 |
2013年 | 17篇 |
2012年 | 17篇 |
2011年 | 18篇 |
2010年 | 21篇 |
2009年 | 30篇 |
2008年 | 21篇 |
2007年 | 20篇 |
2006年 | 35篇 |
2005年 | 9篇 |
2004年 | 13篇 |
2003年 | 16篇 |
2002年 | 9篇 |
2001年 | 9篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 31篇 |
1997年 | 51篇 |
1996年 | 46篇 |
1995年 | 33篇 |
1994年 | 33篇 |
1993年 | 36篇 |
1992年 | 19篇 |
1991年 | 11篇 |
1990年 | 14篇 |
1989年 | 14篇 |
1988年 | 21篇 |
1987年 | 14篇 |
1986年 | 7篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 11篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1976年 | 15篇 |
1975年 | 10篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有764条查询结果,搜索用时 15 毫秒
91.
The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience 总被引:1,自引:0,他引:1
At Stanford University, between 1968 and 1978, 230 patients with pathologic stage I--II Hodgkin's disease were treated on prospective clinical trials with either irradiation alone or irradiation followed by 6 cycles of adjuvant combination chemotherapy. The actuarial survival at 10 yr was 84% for patients in either treatment group. Freedom from relapse at 10 yr was 77% among patients treated with irradiation alone and 84% after treatment with combined modality therapy [p(Gehan) = 0.09]. Freedom from second relapse at 10 yr was 89% and 94%, respectively [p(Gehan) = 0.56]. Several prognostic factors were evaluated in order to identify patients at high risk for relapse or with poor ultimate survival after initial treatment with irradiation alone. Systemic symptoms, histologic subtype, age, and limited extranodal involvement (E-lesions) did not affect the prognosis of patients and failed to identify patients whose survival could be improved by the routine use of combined modality therapy. Patients with large mediastinal masses (mediastinal mass ratio greater than or equal to 1/3) had a significantly poorer freedom from relapse when treated with irradiation alone than when treated initially with combined modality therapy [45% versus 81% at 10 yr, p(Gehan) = 0.03). The 10-yr survival of these patients, however, was not significantly different (84% versus 74%). The implications of these observations on the management of patient with early stage Hodgkin's disease are discussed. 相似文献
92.
Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers 总被引:2,自引:0,他引:2
G J Gormley E Stoner R S Rittmaster H Gregg D L Thompson K C Lasseter P H Vlasses E A Stein 《The Journal of clinical endocrinology and metabolism》1990,70(4):1136-1141
Finasteride, a 5 alpha-reductase inhibitor, was administered to normal male volunteers in a blinded placebo-controlled study at daily oral doses of 25, 50, and 100 mg for 11 days (part 1) and daily oral doses of 0.04, 0.12, 0.2, and 1.0 mg for 14 days (part 2). Results from part 1 showed a significant reduction in dihydrotestosterone (DHT) at all doses and a significant increase in both testosterone (T) and delta 4-androstenedione at the 50- and 100-mg doses. No change was seen in LH, FSH, cortisol, or estradiol levels. Serum lipids, including total cholesterol, low density lipoprotein, high density lipoprotein, and triglycerides were not affected by treatment. Results from part 2 again showed significant reduction in DHT at all doses. DHT levels returned to pretreatment values within 14 days of discontinuing treatment. Significant increases in T were observed only in the 1.0 mg group and only during the first 8 days of treatment. The T/DHT ratio increased with all doses and returned to baseline when drug was discontinued. The DHT metabolites and androstanediol glucuronide and androsterone glucuronide were significantly reduced at all doses. There were no significant adverse experiences reported during part 1 or 2. In conclusion, finasteride is well tolerated by normal volunteers and results in significant suppression of serum DHT at all doses tested. 相似文献
93.
Snyder DS; Negrin RS; O'Donnell MR; Chao NJ; Amylon MD; Long GD; Nademanee AP; Stein AS; Parker PM; Smith EP 《Blood》1994,84(5):1672-1679
Ninety-four consecutive patients with chronic myelogenous leukemia in first clinical chronic phase, median age of 34.0 years (range, 6.8 to 52.4 years), with a histocompatible sibling donor, were treated with fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation (BMT). The median time from diagnosis to BMT was 7.0 months (range, 2.3 to 72.0 months). Sixty patients were treated before BMT with hydroxyurea alone, four patients with busulfan alone, one patient with interferon alone, and the other 29 patients were treated with various combinations of these drugs. Cumulative probabilities of overall survival, event- free survival, and relapse at 5 years were 73%, 64%, and 14%, respectively. The median follow-up time for surviving patients was 38 months, ranging from 12 to 88 months. By stepwise Cox regression analysis, significant prognostic variables were age at transplant, acute graft-versus-host disease > or = grade II, cytomegalovirus- associated interstitial pneumonitis, and years from diagnosis to BMT. 相似文献
94.
Chronic myelocytic leukemia (CML) is a clonal disorder involving neutrophil, monocyte, erythrocyte, and platelet precursors. In order to determine if the eosinophils are also involved in the leukemic clone, we purified the eosinophils from a woman heterozygous for the common electrophoretic variants of the G6PD gene. Only type B enzyme was demonstrable in the eosinophils, neutrophils, and red cells, but both A and B enzymes were found in the fibroblasts. The data provide evidence that the eosinophil is involved in the malignant clone. 相似文献
95.
96.
97.
98.
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma 总被引:14,自引:3,他引:11
Houldsworth J; Mathew S; Rao PH; Dyomina K; Louie DC; Parsa N; Offit K; Chaganti RS 《Blood》1996,87(1):25-29
99.
100.
A gradient in the duration of the G1 phase in the murine neocortical proliferative epithelium 总被引:8,自引:6,他引:2
Miyama S; Takahashi T; Nowakowski RS; Caviness VS Jr 《Cerebral cortex (New York, N.Y. : 1991)》1997,7(7):678-689
Neuronogenesis in the neocortical pseudostratified ventricular epithelium
(PVE) is initiated rostrolaterally and progresses caudo- medially as
development progresses. Here we have measured the cytokinetic parameters
and the fractional neuronal output parameter, Q, of laterally located
early-maturing regions over the principal embryonic days (E12-E15) of
neocortical neuronogenesis in the mouse. These measures are compared with
ones previously made of a medial, late- maturing portion of the PVE.
Laterally, as medially, the duration of the neuronogenetic interval is 6
days and comprises 11 integer cell cycles. Also, in both lateral and medial
areas the length of G1 phase (TG1) increases nearly 4-fold and is the only
cell cycle parameter to change. Q progresses essentially identically
laterally and medially with respect to the succession of integer cell
cycles. Most importantly, from E12 to E13 there is a steeply declining
lateral to medial gradient in TG1. The gradient is due both to the lateral
to medial graded stage of neuronogenesis and to the stepwise increase in
TG1 with each integer cycle during the neuronogenetic interval. To our
knowledge this gradient in TG1 of the cerebral PVE is the first cell
biological gradient to be demonstrated experimentally in such an extensive
proliferative epithelial sheet. We suggest that this gradient in TG1 is the
cellular mechanism for positionally encoding a protomap of the neocortex
within the PVE.
相似文献